Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty.
Priya VartJawad H ButtNiels JongsMeir SchechterGlenn M ChertowDavid Collins WheelerRoberto Flavio Pecoits-FilhoAnna Maria LangkildeRicardo Correa-RotterEllen BurgessJohn J V McMurrayHiddo J L HeerspinkPublished in: The journals of gerontology. Series A, Biological sciences and medical sciences (2023)
The relative benefit of dapagliflozin for all outcomes was consistent across all frailty categories, with no difference in associated safety.